These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Active targeting schemes for nanoparticle systems in cancer therapeutics. Byrne JD; Betancourt T; Brannon-Peppas L Adv Drug Deliv Rev; 2008 Dec; 60(15):1615-26. PubMed ID: 18840489 [TBL] [Abstract][Full Text] [Related]
3. The advent of targeted therapeutics and implications for pathologists. Hess JL Am J Clin Pathol; 2002 Mar; 117(3):355-7. PubMed ID: 11888074 [No Abstract] [Full Text] [Related]
4. Optimizing the delivery of cancer drugs that block angiogenesis. Cao Y; Langer R Sci Transl Med; 2010 Jan; 2(15):15ps3. PubMed ID: 20371469 [TBL] [Abstract][Full Text] [Related]
5. Is there a case for selectively promiscuous anticancer drugs? Fernández A; Crespo A; Tiwari A Drug Discov Today; 2009 Jan; 14(1-2):1-5. PubMed ID: 19038361 [TBL] [Abstract][Full Text] [Related]
6. Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy. Chaplin DJ; Hill SA Curr Opin Investig Drugs; 2002 Sep; 3(9):1381-4. PubMed ID: 12498016 [No Abstract] [Full Text] [Related]
7. Targeted cancer therapeutics: the heartbreak of success. Mann DL Nat Med; 2006 Aug; 12(8):881-2. PubMed ID: 16892027 [No Abstract] [Full Text] [Related]
8. [Targeted therapy of dermatofibrosarcoma with imatinib]. Ugurel S J Dtsch Dermatol Ges; 2007 Mar; 5(3):261. PubMed ID: 17338806 [No Abstract] [Full Text] [Related]
9. Progressive thoughts about progressive disease. Shah NP Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748 [No Abstract] [Full Text] [Related]
10. Advances in molecular targets and cancer therapeutics. Westwell AD Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538 [No Abstract] [Full Text] [Related]
12. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Roukos DH; Tzakos A; Zografos G Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000 [No Abstract] [Full Text] [Related]
13. [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia]. Lange T; Pelz-Ackermann O; Burkhardt R; Niederwieser D Dtsch Med Wochenschr; 2006 Oct; 131(43):2390-4. PubMed ID: 17054054 [No Abstract] [Full Text] [Related]
14. Potential role of vascular targeted therapy to combat against tumor. Chen B; Jin H; Wu K Expert Opin Drug Deliv; 2009 Jul; 6(7):719-26. PubMed ID: 19538038 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenesis: new frontiers in therapeutic development. LaMontagne KR Angiogenesis; 2005; 8(4):285-7. PubMed ID: 16400519 [No Abstract] [Full Text] [Related]
16. Molecular-targeted therapies: lessons from years of clinical development. Rosa DD; Ismael G; Lago LD; Awada A Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917 [TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Cao Y Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094 [TBL] [Abstract][Full Text] [Related]
18. Targeting the molecular basis for tumour hypoxia. Carroll VA; Ashcroft M Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177 [TBL] [Abstract][Full Text] [Related]
19. Targeting the unmet medical need: the Abbott Laboratories oncology approach. Carlson DM; Steinberg JL; Gordon G Clin Adv Hematol Oncol; 2005 Sep; 3(9):703-10. PubMed ID: 16224444 [TBL] [Abstract][Full Text] [Related]